Acyclovir and Difluprednate drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Acyclovir (acyclovir) and Difluprednate (difluprednate). Common drug interactions include erythema multiforme among females and haemolytic anaemia among males.

The phase IV clinical study analyzes what interactions people have when they take Acyclovir and Difluprednate. It is created by eHealthMe based on reports of 15 people who take the same drugs from the FDA, and is updated regularly.

What is Acyclovir?

Acyclovir has active ingredients of acyclovir. It is often used in herpes simplex. eHealthMe is studying from 54,961 Acyclovir users. Check the latest studies of Acyclovir.

What is Difluprednate?

Difluprednate has active ingredients of difluprednate. eHealthMe is studying from 977 Difluprednate users. Check the latest studies of Difluprednate.



On Aug, 06, 2026

15 people who take Acyclovir and Difluprednate together, and have interactions are studied.

Acyclovir and Difluprednate drug interactions.

What are the common drug interactions of Acyclovir and Difluprednate, by gender? *:

female:

  1. Erythema multiforme (a type of hypersensitivity reaction)
  2. Erythema of eyelid (redness of the eyelid)
  3. Eye inflammation
  4. Eye irritation
  5. Fall
  6. Memory impairment
  7. Skin infection
  8. Stevens-johnson syndrome (an immune-complex-mediated hypersensitivity disorder. it ranges from mild skin and mucous membrane lesions to a severe)
  9. Eye pain
  10. Atopy (a genetic disposition to develop an allergic reaction)

male:

  1. Haemolytic anaemia (anaemia due to haemolysis)
  2. Idiopathic thrombocytopenic purpura (bleeding disorder in which the immune system destroys platelets, which are necessary for normal blood clotting)
  3. Cerebral haemorrhage (bleeding within the brain)
  4. Hypertriglyceridaemia (excess of triglycerides in the blood)
  5. Meningitis cryptococcal (bacterial inflammation of the protective membranes covering the brain and spinal cord, known collectively as the meninges)
  6. Acute graft versus host disease (acute complication following an allogeneic tissue/blood transplant)
  7. Lung neoplasm malignant (cancer tumour of lung)

What are the common drug interactions of Acyclovir and Difluprednate, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

  1. Haemolytic anaemia (anaemia due to haemolysis)
  2. Idiopathic thrombocytopenic purpura (bleeding disorder in which the immune system destroys platelets, which are necessary for normal blood clotting)
  3. Cerebral haemorrhage (bleeding within the brain)
  4. Acute graft versus host disease (acute complication following an allogeneic tissue/blood transplant)

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

  1. Erythema multiforme (a type of hypersensitivity reaction)
  2. Skin infection
  3. Stevens-johnson syndrome (an immune-complex-mediated hypersensitivity disorder. it ranges from mild skin and mucous membrane lesions to a severe)
  4. Atopy (a genetic disposition to develop an allergic reaction)

50-59:

  1. Hypertriglyceridaemia (excess of triglycerides in the blood)
  2. Meningitis cryptococcal (bacterial inflammation of the protective membranes covering the brain and spinal cord, known collectively as the meninges)

60+:

  1. Dizziness
  2. Erythema of eyelid (redness of the eyelid)
  3. Eye inflammation
  4. Eye pain
  5. Fall
  6. Lung neoplasm malignant (cancer tumour of lung)
  7. Memory impairment

What are the existing conditions these people have? *

  1. Hyperlipidaemia (presence of excess lipids in the blood): 5 people, 33.33%
  2. Rashes (redness): 4 people, 26.67%
  3. Primary Immunodeficiency Syndrome: 4 people, 26.67%
  4. Insomnia (sleeplessness): 4 people, 26.67%
  5. Hypertriglyceridaemia (excess of triglycerides in the blood): 3 people, 20.00%
  6. Eczema (patches of skin become rough and inflamed, with itching and bleeding blisters): 3 people, 20.00%
  7. Hiv Infection: 3 people, 20.00%
  8. Meningitis Bacterial (bacterial inflammation of the protective membranes covering the brain and spinal cord, known collectively as the meninges): 3 people, 20.00%
  9. Encephalitis Herpes (inflammation of the brain due to herpes infection): 3 people, 20.00%
  10. Nausea (feeling of having an urge to vomit): 2 people, 13.33%

* Approximation only. Some reports may have incomplete information.

Do you take Acyclovir and Difluprednate?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Acyclovir and Difluprednate:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Acyclovir:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Difluprednate:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Acyclovir and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Difluprednate and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Related publications that referenced our studies


How the study uses the data?

The study uses data from the FDA. It is based on acyclovir and difluprednate (the active ingredients of Acyclovir and Difluprednate, respectively), and Acyclovir and Difluprednate (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: